As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought
A slimmed-down BioMarin started the new year open for business, seeking to leverage its unique skillset to strike deals that bolster its pipeline of medicines for genetic diseases.
A slimmed-down BioMarin started the new year open for business, seeking to leverage its unique skillset to strike deals that bolster its pipeline of medicines for genetic diseases.
